Cargando…
Early use of the HPV 2-dose vaccination schedule: Leveraging evidence to support policy for accelerated impact
Although human papillomavirus (HPV) vaccines were initially licensed based on efficacy after three-dose regimens in women aged 15–26 years, it was recognized early in clinical development that comparable immunogenicity could be obtained after just two doses when administered to younger girls. In bot...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Science
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6078939/ https://www.ncbi.nlm.nih.gov/pubmed/29887322 http://dx.doi.org/10.1016/j.vaccine.2018.02.004 |